JP2020520994A5 - - Google Patents

Download PDF

Info

Publication number
JP2020520994A5
JP2020520994A5 JP2020514155A JP2020514155A JP2020520994A5 JP 2020520994 A5 JP2020520994 A5 JP 2020520994A5 JP 2020514155 A JP2020514155 A JP 2020514155A JP 2020514155 A JP2020514155 A JP 2020514155A JP 2020520994 A5 JP2020520994 A5 JP 2020520994A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
halo
cycloalkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020514155A
Other languages
English (en)
Japanese (ja)
Other versions
JP7237941B2 (ja
JP2020520994A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/033544 external-priority patent/WO2018213807A1/en
Publication of JP2020520994A publication Critical patent/JP2020520994A/ja
Publication of JP2020520994A5 publication Critical patent/JP2020520994A5/ja
Application granted granted Critical
Publication of JP7237941B2 publication Critical patent/JP7237941B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020514155A 2017-05-19 2018-05-18 皮膚障害の処置用の融合複素環式芳香族アニリン化合物 Active JP7237941B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508997P 2017-05-19 2017-05-19
US62/508,997 2017-05-19
PCT/US2018/033544 WO2018213807A1 (en) 2017-05-19 2018-05-18 Fused heteroaromatic-aniline compounds for treatment of dermal disorders

Publications (3)

Publication Number Publication Date
JP2020520994A JP2020520994A (ja) 2020-07-16
JP2020520994A5 true JP2020520994A5 (cg-RX-API-DMAC7.html) 2021-07-26
JP7237941B2 JP7237941B2 (ja) 2023-03-13

Family

ID=62620965

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020514155A Active JP7237941B2 (ja) 2017-05-19 2018-05-18 皮膚障害の処置用の融合複素環式芳香族アニリン化合物

Country Status (13)

Country Link
US (2) US10988483B2 (cg-RX-API-DMAC7.html)
EP (1) EP3624795B1 (cg-RX-API-DMAC7.html)
JP (1) JP7237941B2 (cg-RX-API-DMAC7.html)
KR (1) KR102659322B1 (cg-RX-API-DMAC7.html)
CN (1) CN111093658B (cg-RX-API-DMAC7.html)
AU (1) AU2018270292B2 (cg-RX-API-DMAC7.html)
CA (1) CA3063535A1 (cg-RX-API-DMAC7.html)
DK (1) DK3624795T3 (cg-RX-API-DMAC7.html)
ES (1) ES2913213T3 (cg-RX-API-DMAC7.html)
IL (1) IL270576B (cg-RX-API-DMAC7.html)
MA (1) MA49140A (cg-RX-API-DMAC7.html)
MX (1) MX2019013562A (cg-RX-API-DMAC7.html)
WO (1) WO2018213807A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2913213T3 (es) * 2017-05-19 2022-06-01 Nflection Therapeutics Inc Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
WO2020106305A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
EP3883552B1 (en) 2018-11-20 2025-04-09 NFlection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
CN113660931B (zh) * 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物
CN113473986B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤疾病萘啶酮苯胺化合物
CN113645964B (zh) * 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于胎记治疗的芳基苯胺和杂芳基苯胺化合物
CN117157065A (zh) 2021-01-21 2023-12-01 恩福莱克逊治疗有限公司 吡咯并吡啶-苯胺化合物的晶型
MX2024011403A (es) * 2022-03-17 2024-09-23 Springworks Therapeutics Inc Tratamiento con mirdametinib.

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7674907B2 (en) * 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
WO2006083979A2 (en) 2005-02-02 2006-08-10 Nexgenix Pharmaceuticals, L.L.C. Local treatment of neurofibromas
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
GB0601962D0 (en) * 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
CA2660546A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
WO2008024724A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
EP2113500A1 (en) 2006-10-31 2009-11-04 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
CA2672327A1 (en) 2006-11-30 2008-06-05 Genentech, Inc. Aza-indolyl compounds and methods of use
US20080312307A1 (en) 2007-05-25 2008-12-18 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
GB0714384D0 (en) * 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
CA2708176A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
GB0801081D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
WO2009093008A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
GB0801080D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
JP2010043019A (ja) * 2008-08-12 2010-02-25 Taisho Pharmaceutical Co Ltd ピペリジニルピペラジン化合物
AR082453A1 (es) * 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
US9422262B2 (en) 2010-09-24 2016-08-23 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
US9357781B2 (en) 2013-05-03 2016-06-07 Inscent, Inc. Honeybee repellents and uses thereof
CN105384754B (zh) 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
JP7212956B2 (ja) 2017-05-19 2023-01-26 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用のピロロピリジン-アニリン化合物
ES2913213T3 (es) 2017-05-19 2022-06-01 Nflection Therapeutics Inc Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos

Similar Documents

Publication Publication Date Title
JP2020520995A5 (cg-RX-API-DMAC7.html)
WO2021248095A1 (en) Heterocyclic compounds and methods of use thereof
WO2021248083A1 (en) Heterocyclic compounds and methods of use thereof
US20100168125A1 (en) Indolizines and aza-analog derivatives thereof as cns active compounds
CN1284078A (zh) 抑制胃酸分泌的杂环化合物、其制备方法及其药物组合物
EP2098526B1 (en) Nitrogen-containing bicyclic compounds active on chronic pain conditions
KR880005092A (ko) 항궤양제로서 유효한 벤즈이미다졸의 신규 유도체
JP2022539329A (ja) 特発性肺線維症を治療する方法
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
KR101986272B1 (ko) 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도
JP2007507494A5 (cg-RX-API-DMAC7.html)
CN111770756B (zh) 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
EP3391887A1 (en) Wound treatment agent
JP2022529371A5 (cg-RX-API-DMAC7.html)
JP2011518168A5 (cg-RX-API-DMAC7.html)
RU2001121650A (ru) Композиции для лечения кожных заболеваний
JP2022511730A5 (cg-RX-API-DMAC7.html)
JP2010514734A (ja) 腸障害の治療のためのイソソルビドモノニトレート誘導体
WO2008124823A1 (en) Method of treating melanoma
RU2018130097A (ru) Лечение экземы кистей
RU2018114922A (ru) Лечение очаговой алопеции
TWI481611B (zh) 碳環核苷及其醫藥用途及組合物
CN1039384C (zh) 加速创伤愈合的组合物
WO2024050434A1 (en) ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES